Alloin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Alloin
- Accession Number
- DB15477
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Alloin (DB15477)
- Weight
- Average: 418.398
Monoisotopic: 418.126382288 - Chemical Formula
- C21H22O9
- Synonyms
- Aloin
- Aloin, Cape
- Aloin, curaco
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Alloin. Aclidinium The therapeutic efficacy of Alloin can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Alloin can be decreased when used in combination with Alfentanil. Amantadine The therapeutic efficacy of Alloin can be decreased when used in combination with Amantadine. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Alloin. Amiodarone The therapeutic efficacy of Alloin can be decreased when used in combination with Amiodarone. Amitriptyline The therapeutic efficacy of Alloin can be decreased when used in combination with Amitriptyline. Amlodipine The therapeutic efficacy of Alloin can be decreased when used in combination with Amlodipine. Amobarbital The therapeutic efficacy of Alloin can be decreased when used in combination with Amobarbital. Amoxapine The therapeutic efficacy of Alloin can be decreased when used in combination with Amoxapine. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aid-lax Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Nobel Pharm Enr. 1989-12-31 1997-07-31 Canada 
Alsiline Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Alsi Cie Ltee 1978-12-31 1997-08-08 Canada Bicholate Lilas Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Sabex Inc 1991-12-31 1997-10-10 Canada Bilex Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Biodo Enrg 1978-12-31 1997-10-10 Canada Carters Little Pills Tab Alloin (8 mg) + Phenolphthalein (16 mg) Tablet Oral Carter Products, Division Of Carter Wallace Ns Inc. 1978-12-31 1997-08-14 Canada Lax-BO Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Cardinaux Medicinat Inc. 1992-12-31 1996-09-09 Canada Laxatif Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Vitalab 1991-12-31 1997-12-18 Canada Laxative Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Laboratoire Lalco Inc. 1978-12-31 1997-10-10 Canada Laxavite Tab Alloin (12 mg) + Frangula purshiana bark (30 mg) + Phenolphthalein (100 mg) + Sodium taurocholate (60 mg) Tablet Oral Neosol Enrg 1978-12-31 1997-07-29 Canada Robol Tab Alloin (16.2 mg) + Belladonna (5.4 mg) + Ipecac (4.32 mg) + Phenolphthalein (64.8 mg) Tablet Oral Labs Anglo French 1979-12-31 1997-08-05 Canada
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- W41H6S09F4
- CAS number
- 8015-61-0
- InChI Key
- AFHJQYHRLPMKHU-CGISPIQUSA-N
- InChI
- InChI=1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13-14,17,19-26,28-29H,6-7H2/t13-,14?,17-,19+,20-,21+/m1/s1
- IUPAC Name
- 1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-9,10-dihydroanthracen-9-one
- SMILES
- OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(CO)C=C2O
References
- General References
- Not Available
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.63 mg/mL ALOGPS logP -0.49 ALOGPS logP 0.41 ChemAxon logS -2.2 ALOGPS pKa (Strongest Acidic) 8.31 ChemAxon pKa (Strongest Basic) -2.9 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 9 ChemAxon Hydrogen Donor Count 7 ChemAxon Polar Surface Area 167.91 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 103.79 m3·mol-1 ChemAxon Polarizability 40.97 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on August 30, 2019 15:38 / Updated on June 12, 2020 16:53